Gilead Sciences, Inc., incorporated on June 22, 1987, is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its Nimbus Apollo program includes the candidate NDI-010976, a hepatotropic allosteric Acetyl-CoA Carboxylase (ACC) inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the treatment of hepatocellular carcinoma (HCC) and other diseases. Its Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.
The Company competes with ViiV Healthcare, AbbVie Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Janssen Therapeutics, Novartis Pharmaceuticals Corporation, Actelion Pharmaceuticals US, Inc., United Therapeutics Corporation, Pfizer Inc., Pharmacyclics, Inc., Roche Group, Cephalon, Inc., GlaxoSmithKline, Enzon Pharmaceuticals, Inc., Zeneus Pharma Ltd., Three Rivers Pharmaceuticals, LLC and Genpharma, S.A.